Regenxbio Inc. (NASDAQ:RGNX) saw an uptick in trading volume on Friday . 117,660 shares changed hands during trading, an increase of 13% from the previous session’s volume of 104,151 shares.The stock last traded at $11.18 and had previously closed at $9.97.

A number of research firms recently commented on RGNX. Zacks Investment Research upgraded Regenxbio from a “sell” rating to a “hold” rating in a research report on Thursday, April 14th. Piper Jaffray Cos. reissued a “buy” rating and set a $33.00 price target on shares of Regenxbio in a report on Tuesday, July 5th. Finally, Chardan Capital reissued a “buy” rating on shares of Regenxbio in a report on Tuesday, May 10th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $28.35.

The stock’s 50 day moving average is $8.28 and its 200-day moving average is $10.97. The company’s market capitalization is $302.89 million.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. On average, equities research analysts expect that Regenxbio Inc. will post ($2.31) EPS for the current fiscal year.

In other news, insider Fmr Llc sold 18,300 shares of the firm’s stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $12.41, for a total value of $227,103.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

An institutional investor recently raised its position in Regenxbio stock. RS Investment Management Co. LLC raised its position in Regenxbio Inc. (NASDAQ:RGNX) by 11.3% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 746,592 shares of the company’s stock after buying an additional 75,810 shares during the period. RS Investment Management Co. LLC owned 2.84% of Regenxbio worth $12,393,000 at the end of the most recent quarter.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.